Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 3/20 | 0.63 |
| ▸ | RHOA | P61586 | 1/20 | 0.59 |
| ▸ | SNCA | P37840 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.44 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31661371 | 1.00 | CASP6 (0.63) | CASP6RHOASNCAALDH1A1KDM4E | |
| Potassium SCHEMBL7615456 | 0.99 | CASP6 (0.61) | CASP6RHOASNCAALDH1A1KDM4E | |
| SCHEMBL2293946 | 0.89 | CASP6 (0.49) | CASP6RHOASNCAALDH1A1KDM4E | |
| SCHEMBL25385245 | 0.87 | CASP6 (0.50) | CASP6RHOASNCAALDH1A1KDM4E | |
| SCHEMBL7046526 | 0.83 | CASP6 (0.62) | CASP6RHOASNCAALDH1A1KDM4E | |
| SCHEMBL31614400 | 0.82 | SNCA (0.63) | CASP6RHOASNCAALDH1A1KDM4E | |
| SCHEMBL291102 | 0.82 | SNCA (0.63) | CASP6RHOASNCAALDH1A1KDM4E | |
| SCHEMBL4303416 | 0.82 | CASP6 (0.73) | CASP6RHOASNCAALDH1A1KDM4E | |
| SCHEMBL7037608 | 0.82 | CASP6 (0.59) | CASP6RHOASNCAALDH1A1KDM4E | |
| Ammonia Solution, Strong SCHEMBL28873814 | 0.81 | CASP6 (0.57) | CASP6RHOASNCAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076072-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2011-12-13 | — | — | US | claimed |
| US-8026057-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2011-09-27 | — | — | US | claimed |
| US-7468243-B2 | Nucleotide sequence labelling compoumd four use as tool in genetic engineering | AFFYMETRIX, INC. (US) | 2008-12-23 | — | — | US | claimed |
| US-7291463-B2 | Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis | AFFYMETRIX, INC. (US) | 2007-11-06 | — | — | US | claimed |
| US-7282327-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2007-10-16 | — | — | US | claimed |
| US-5298197-A | Chemiluminescent microemulsions | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1994-03-29 | — | — | US | claimed |
| US-12297221-B2 | Functionalization and purification of molecules by reversible group exchange | ILLUMINA, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240384262-A1 | LINKING SEQUENCE READS USING PAIRED CODE TAGS | ILLUMINA, INC. | 2024-11-21 | — | — | US | disclosed |
| US-11993772-B2 | Linking sequence reads using paired code tags | ILLUMINA, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20230406874-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | ILLUMINA, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11760772-B2 | Functionalization and purification of molecules by reversible group exchange | ILLUMINA, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210277043-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | ILLUMINA, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-11021504-B2 | Functionalization and purification of molecules by reversible group exchange | ILLUMINA, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-4256834-A | REPRESSING THE SIGNALS PRODUCED BY UNBOUND LABELS; SENSITIVITY | SYVA COMPANY (US) | 1981-03-17 | — | — | US | disclosed |
| EP-0022768-A1 | MACROMOLECULAR ENVIRONMENT CONTROL IN SPECIFIC RECEPTOR ASSAYS. | SYVA CO (US) | 1981-01-28 | — | — | EP | disclosed |
| EP-0017908-A1 | A method for determining the presence in a sample of an analyte and a kit for use in this method | SYVA COMPANY (US) | 1980-10-29 | — | — | EP | disclosed |
| EP-0015695-A1 | Support-ligand analog-fluorescer conjugate and serum assay method involving such conjugate | SYVA COMPANY (US) | 1980-09-17 | — | — | EP | disclosed |
| EP-0022768-A4 | MACROMOLECULAR ENVIRONMENT CONTROL IN SPECIFIC RECEPTOR ASSAYS. | SYVA CO (US) | 1980-08-18 | — | — | EP | disclosed |
| US-4193983-A | Labeled liposome particle compositions and immunoassays therewith | SYVA COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| WO-1979000882-A1 | MACROMOLECULAR ENVIRONMENT CONTROL IN SPECIFIC RECEPTOR ASSAYS | SYVA CO (US) | 1979-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406874-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | PHAX, ALKBH1, JMJD6 | CASP6 4521/4885RHOA 1143/4885SNCA 2528/4885 |
| US-11021504-B2 | Functionalization and purification of molecules by reversible group exchange | PHAX, ALKBH1, JMJD6 | CASP6 4521/4885RHOA 1143/4885SNCA 2528/4885 |
| US-20210277043-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | PHAX, ALKBH1, JMJD6 | CASP6 4521/4885RHOA 1143/4885SNCA 2528/4885 |
| US-12297221-B2 | Functionalization and purification of molecules by reversible group exchange | PHAX, ALKBH1, JMJD6 | CASP6 4521/4885RHOA 1143/4885SNCA 2528/4885 |
| US-11760772-B2 | Functionalization and purification of molecules by reversible group exchange | PHAX, ALKBH1, JMJD6 | CASP6 4521/4885RHOA 1143/4885SNCA 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.